Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir (II): A pediatric drug use investigation

Journal of Infection and Chemotherapy

Volumn 21, Issue 3, 2014, Pages 194-201

  Komeda, Takuji ^a   Ishii, Shingo ^a   Itoh, Yumiko ^a   Ariyasu, Yasuyuki ^a   Sanekata, Masaki ^a   Yoshikawa, Takayoshi ^a   Shimada, Jingoro ^b  

^a SHIONOGI AND CO LTD   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Abnormal behavior; Influenza; Pediatric; Peramivir; Post marketing surveillance; Safety profile

Indexed keywords

ASPARTATE AMINOTRANSFERASE; PERAMIVIR; ANTIVIRUS AGENT; CYCLOPENTANE DERIVATIVE; ENZYME INHIBITOR; GUANIDINE DERIVATIVE; SIALIDASE;

ABDOMINAL PAIN; ABNORMAL BEHAVIOR; ADOLESCENT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CONSTIPATION; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ECZEMA; ERYTHEMA; ERYTHEMA MULTIFORME; EVALUATION STUDY; EYE PAIN; FACE EDEMA; FATIGUE; FEMALE; FEVER; HEART PALPITATION; HUMAN; HYPERTHERMIA; INCIDENCE; INFANT; INFLUENZA; JAPAN; LEUKOPENIA; MALE; NAUSEA; NEUTROPHIL COUNT; NEWBORN; PERIPHERAL EDEMA; PETECHIA; PHOTOPHOBIA; POSTMARKETING SURVEILLANCE; RASH; RISK FACTOR; SIDE EFFECT; STOMATITIS; TREMOR; UNCONSCIOUSNESS; URTICARIA; VERTIGO; VOMITING; ANTAGONISTS AND INHIBITORS; BEHAVIOR DISORDER; CHEMICALLY INDUCED; CLINICAL TRIAL; INFLUENZA, HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MULTICENTER STUDY; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; CHILD BEHAVIOR DISORDERS; CHILD, PRESCHOOL; CYCLOPENTANES; DIARRHEA; ENZYME INHIBITORS; FEMALE; GUANIDINES; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA, HUMAN; INJECTIONS, INTRAVENOUS; MALE; NEURAMINIDASE; PRODUCT SURVEILLANCE, POSTMARKETING; TREATMENT OUTCOME;

EID: 84937721536     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2014.11.009     Document Type: Article

References (12)

1. Kohno S., Kida H., Mizuguchi M., Shimada J. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother 2010, 54:4568-4574.
2. Kohno S., Kida H., Mizuguchi M., Hirotsu N., Ishida T., Kadota J., et al. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. Antimicrob Agents Chemother 2011, 55:2803-2812.
3. Kohno S., Yen M.Y., Cheong H.J., Hirotsu N., Ishida T., Kadota J., et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother 2011, 55:5267-5276.
4. Sugaya N., Kohno S., Ishibashi T., Wajima T., Takahashi T. Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection. Antimicrob Agents Chemother 2012, 56:369-377.
5. Peltola V., Ziegler T., Ruuskanen O. Influenza A and B virus infections in children. Clin Infect Dis 2003, 36:299-305.
6. Reports on side effects in teenager with respect to cases with downfall and jumping off after taking oseltamivir. [accessed 08.01.14]. http://www.mhlw.go.jp/houdou/2007/03/h0321-1.html.
7. Abnormal behavior after taking oseltamivir. [accessed 08.01.14]. http://www.mhlw.go.jp/houdou/2007/03/h0320-1.html.
8. Investigation on the circumstances surrounding the occurrence of symptoms accompanying influenza. [accessed 08.01.14]. http://www.mhlw.go.jp/shingi/2009/06/dl/s0616-4g.pdf.
9. Investigation on the gathering of information on abnormal behavior (occurring) at the time of acquiring influenza-like disease (Report of the 2009/2010 Season). [accessed 08.01.14]. http://www.mhlw.go.jp/shingi/2009/06/dl/s0616-4h.pdf.
10. Kashiwagi S., Yoshida S., Yamaguchi H., Niwa S., Mitsui N., Tanigawa M., et al. Safety of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate in post-marketing surveillance. Int J Antimicrob Agents 2012, 40:381-388.
11. Hernandez J., Alexander W.J., Kohno S., Elder J., Sheridan W. Neutropenia is not related to neuraminidase inhibitor (NAI) therapy of influenza in phase 2 and 3 controlled clinical trials. 48th annual meeting of the Infectious Diseases Society of America (IDSA); 10/22/2010; Vancouver, BC 2010, 765.
12. Kashiwagi S., Yoshida S., Yamaguchi H., Mitsui N., Tanigawa M., Shiosakai K., et al. Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance. J Infect Chemother 2013, 19:223-232.